A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Inclusion Criteria: * Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined by estrogen receptor \[ER\] \< 1%, progesterone receptor \[PR\] \< 1% and HER2 1+ or less by immunohistochemistry \[IHC\]; if HER-2 expression is 2+, a negative fluorescence in situ hybridization \[FISH\] testing is required) (c) pancreatic adenocarcinoma (PDAC), or (d) small cell lung cancer (SCLC) * Must have received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type; for NSCLC, it is either PD-1/PD-L1 inhibitor, or platinum-containing chemotherapy, or an EGFR tyrosine kinase inhibitor or an ALK inhibitor if sensitizing mutation present; TNBC: platinum-containing chemotherapy; PDAC: fluorouracil (5-FU-), gemcitabine-, or taxane-containing chemotherapy either with or without radiation therapy; SCLC: platinum-containing chemotherapy for limited or extensive stage disease * Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 * Toxicities of prior therapy (except alopecia) should be resolved to =\< grade 1 as per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0; patients with long-standing stable grade 2 neuropathy or prior grade 2 treatment-related hypothyroidism requiring tr…